- Home
- EMAT vs VKTX Comparison
EMAT vs VKTX Comparison
Compare EMAT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMAT | VKTX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | EMAT | VKTX |
|---|---|---|
| Price | $9.20 | $31.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $30.00 | ★ $95.86 |
| AVG Volume (30 Days) | 102.4K | ★ 2.2M |
| Earning Date | 05-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,122.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $22.96 |
| 52 Week High | $17.50 | $43.15 |
Technical Indicators
Market Signals| Indicator | EMAT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 44.63 |
| Support Level | $6.61 | $30.64 |
| Resistance Level | $15.00 | $36.09 |
| Average True Range (ATR) | 0.73 | 1.65 |
| MACD | 0.13 | -0.42 |
| Stochastic Oscillator | 63.95 | 38.21 |
Price Performance
Historical ComparisonAbout EMAT Evolution Metals & Technologies Corp. Common Stock
Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.